The Differences in the Safety and Tolerability of Immune Checkpoint Inhibitors as Treatment for Non–Small Cell Lung Cancer and Melanoma: Network Meta-Analysis and Systematic Review

Background: Immune checkpoint inhibitors (ICIs) have evolved for the treatment of solid tumors. In addition to the efficacy of ICIs for cancer, the adverse events (AEs) of ICIs are also noteworthy for gradually more extensive clinical use. Objective: To conduct a systematic review and network meta-a...

Descripción completa

Detalles Bibliográficos
Autores principales: Chai, Qing-Qing, Du, Jiang-Yang, Zhu, Jun, Wu, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6821878/
https://www.ncbi.nlm.nih.gov/pubmed/31708783
http://dx.doi.org/10.3389/fphar.2019.01260

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6821878/
https://www.ncbi.nlm.nih.gov/pubmed/31708783
http://dx.doi.org/10.3389/fphar.2019.01260

Ejemplares similares